Acquired Company

GSK completed the acquisition of Bellus Health on 6/28/2023 by way of a plan of arrangement, acquiring Bellus Health for cash per share as part of a roughly US$2.0 billion deal.

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. The Company's product candidate, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus. Show more

275 Armand-Frappier Blvd, Quebec, H7V 4A7, Canada

www.bellushealth.com

Pharmaceutical Preparation Manufacturing

Manufacturing

Start AI Chat

Market Cap

0.00

52 Wk Range

$N/A - $N/A

Previous Close

$14.74

Open

$14.74

Volume

3,449,256

Day Range

$14.74 - $14.75

Enterprise Value

0.00

Cash

0.00

Avg Qtr Burn

N/A

Insider Ownership

10.26%

Institutional Own.

90.41%

Qtr Updated

06/30/24

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
BLU-5937 (P2X3 antagonist) Details Chronic pruritus, Atopic pruritus	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.